» Articles » PMID: 22677193

Dysregulated Krüppel-like Factor 4 and Vitamin D Receptor Signaling Contribute to Progression of Hepatocellular Carcinoma

Overview
Specialty Gastroenterology
Date 2012 Jun 9
PMID 22677193
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Krüppel-like factor 4 (KLF4) is a transcription factor and putative tumor suppressor. However, little is known about its effects in hepatocellular carcinogenesis. We investigated the clinical significance, biologic effects, and mechanisms of dysregulated KLF4 signaling.

Methods: We performed microarray analysis of hepatocellular carcinoma (HCC) tissues. We used molecular biology analyses and animal models to evaluate activation and function of KLF4-vitamin D receptor (VDR) pathway.

Results: Expression of KLF4 protein was decreased or lost in primary HCC samples, in particular, lymph node metastases, compared with normal liver tissues. Loss of KLF4 from primary tumors was significantly associated with reduced survival time and was identified as a prognostic marker. Most human HCC cell lines had losses or substantial decreases in levels of KLF4. Exogenous expression of KLF4 in HCC cells upregulated expression of mesenchymal-epithelial transition (MET) and inhibited their migration, invasion, and proliferation in vitro. When these cells were injected into mice, tumors grew more slowly and metastasis was inhibited, compared with HCC cells that did not express KLF4. VDR is a direct transcriptional target of KLF4; we identified 2 sites in the VDR promoter that bound specifically to KLF4. Increased expression of VDR sensitized tumor cells to the inhibitory effects of vitamin D.

Conclusions: KLF4 binds to the promoter of VDR to regulate its expression; levels of KLF4 are reduced and levels of VDR are increased in HCC cell lines and primary tumor samples. Expression of KLF4 in HCC cells sensitizes them to the anti-proliferative effects of VD3. This pathway might be manipulated to prevent or treat liver cancer.

Citing Articles

KLF4 Suppresses the Progression of Hepatocellular Carcinoma by Reducing Tumor ATP Synthesis through Targeting the Mir-206/RICTOR Axis.

Wang Y, Zuo D, Huang Z, Qiu Y, Wu Z, Liu S Int J Mol Sci. 2024; 25(13).

PMID: 39000273 PMC: 11240942. DOI: 10.3390/ijms25137165.


Cancer stem cells: a target for overcoming therapeutic resistance and relapse.

Zhang S, Yang R, Ouyang Y, Shen Y, Hu L, Xu C Cancer Biol Med. 2024; .

PMID: 38164743 PMC: 10845928. DOI: 10.20892/j.issn.2095-3941.2023.0333.


Loss of the vitamin D receptor triggers senescence in chronic myeloid leukemia via DDIT4-mediated DNA damage.

Xu Y, Qi W, Zheng C, Li Y, Lu Z, Guan J J Mol Cell Biol. 2023; 15(10).

PMID: 37880985 PMC: 11190374. DOI: 10.1093/jmcb/mjad066.


KLF4 transcription factor in tumorigenesis.

He Z, He J, Xie K Cell Death Discov. 2023; 9(1):118.

PMID: 37031197 PMC: 10082813. DOI: 10.1038/s41420-023-01416-y.


New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy.

Zeng L, Zhu Y, Moreno C, Wan Y Semin Cancer Biol. 2023; 90:29-44.

PMID: 36806560 PMC: 10023514. DOI: 10.1016/j.semcancer.2023.02.003.


References
1.
Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L . Vitamin D3: a helpful immuno-modulator. Immunology. 2011; 134(2):123-39. PMC: 3194221. DOI: 10.1111/j.1365-2567.2011.03482.x. View

2.
Whittaker S, Marais R, Zhu A . The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010; 29(36):4989-5005. DOI: 10.1038/onc.2010.236. View

3.
Caputo A, Pourgholami M, Akhter J, Morris D . 1,25-Dihydroxyvitamin D(3) induced cell cycle arrest in the human primary liver cancer cell line HepG2. Hepatol Res. 2003; 26(1):34-39. DOI: 10.1016/s1386-6346(02)00328-5. View

4.
Yang J, Nakamura I, Roberts L . The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2010; 21(1):35-43. PMC: 3050428. DOI: 10.1016/j.semcancer.2010.10.007. View

5.
Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg K, Lofts F . A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer. 2003; 89(2):252-7. PMC: 2394267. DOI: 10.1038/sj.bjc.6601104. View